Farnesyltransferase Inhibitors: A New Class of Cancer Chemotherapeutics

Biochemical Society Transactions - United Kingdom
doi 10.1042/bst0240688
Full Text
Abstract

Available in full text

Categories
Biochemistry
Date
Authors
Publisher

Portland Press Ltd.

Related search

The Potential of Farnesyltransferase Inhibitors as Cancer Chemotherapeutics

Annual Review of Pharmacology and Toxicology
ToxicologyPharmacology
1997English

A Mutant Form of Human Protein Farnesyltransferase Exhibits Increased Resistance to Farnesyltransferase Inhibitors

Journal of Biological Chemistry
BiochemistryCell BiologyMolecular Biology
1999English

New Targeted Therapies in Myelodysplastic Syndrome: The Role of Farnesyltransferase and Proteasome Inhibitors

BMC Proceedings
BiochemistryMedicineGeneticsMolecular Biology
2010English

Kinase Inhibitors: A New Class of Antirheumatic Drugs

Drug Design, Development and Therapy
Drug DiscoveryPharmacologyPharmaceutical Science
2012English

High Affinity for Farnesyltransferase and Alternative Prenylation Contribute Individually to K-Ras4B Resistance to Farnesyltransferase Inhibitors

Journal of Biological Chemistry
BiochemistryCell BiologyMolecular Biology
2003English

Immune Response Checkpoint Inhibitors: New Risks of a New Class of Antitumor Agents

Safety and Risk of Pharmacotherapy
2020English

Alogliptin: A New Addition to the Class of DPP-4 Inhibitors

Diabetes, Metabolic Syndrome and Obesity: Targets and Therapy
Internal MedicinePharmacology
2009English

SAR Studies for a New Class of Antibacterial NAD Biosynthesis Inhibitors

Journal of Combinatorial Chemistry
2009English

“Reverse” Carbocyclic Fleximers: Synthesis of a New Class of Adenosine Deaminase Inhibitors

Nucleosides, Nucleotides and Nucleic Acids
MedicineBiochemistryGeneticsMolecular Medicine
2013English

Amanote Research

Note-taking for researchers

Follow Amanote

© 2024 Amaplex Software S.P.R.L. All rights reserved.

Privacy PolicyRefund Policy